SG11201408013WA - Solid forms of an antiviral compound - Google Patents
Solid forms of an antiviral compoundInfo
- Publication number
- SG11201408013WA SG11201408013WA SG11201408013WA SG11201408013WA SG11201408013WA SG 11201408013W A SG11201408013W A SG 11201408013WA SG 11201408013W A SG11201408013W A SG 11201408013WA SG 11201408013W A SG11201408013W A SG 11201408013WA SG 11201408013W A SG11201408013W A SG 11201408013WA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- compound
- gilead sciences
- rule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655934P | 2012-06-05 | 2012-06-05 | |
| US201361759295P | 2013-01-31 | 2013-01-31 | |
| US13/800,374 US8969588B2 (en) | 2012-06-05 | 2013-03-13 | Solid forms of an antiviral compound |
| PCT/US2013/044138 WO2013184698A1 (en) | 2012-06-05 | 2013-06-04 | Solid forms of an antiviral compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408013WA true SG11201408013WA (en) | 2015-01-29 |
Family
ID=49670993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408013WA SG11201408013WA (en) | 2012-06-05 | 2013-06-04 | Solid forms of an antiviral compound |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8969588B2 (pt) |
| EP (1) | EP2855478B1 (pt) |
| JP (2) | JP2015518891A (pt) |
| KR (1) | KR20150028971A (pt) |
| CN (2) | CN104379584A (pt) |
| AR (1) | AR091259A1 (pt) |
| AU (1) | AU2013271768B2 (pt) |
| BR (1) | BR112014030400A2 (pt) |
| CA (1) | CA2875507A1 (pt) |
| ES (1) | ES2694759T3 (pt) |
| HK (1) | HK1205127A1 (pt) |
| IL (1) | IL236004A0 (pt) |
| IN (1) | IN2014MN02644A (pt) |
| MX (1) | MX2014014563A (pt) |
| PT (1) | PT2855478T (pt) |
| RU (1) | RU2014150437A (pt) |
| SG (1) | SG11201408013WA (pt) |
| TW (1) | TW201408661A (pt) |
| UY (1) | UY34844A (pt) |
| WO (1) | WO2013184698A1 (pt) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005003147A2 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| NZ706236A (en) | 2009-05-13 | 2016-07-29 | Gilead Pharmasset Llc | Antiviral compounds |
| BR112013028886A2 (pt) | 2011-05-10 | 2016-08-09 | Gilead Sciences Inc | compostos heterocíclicos fundidos como moduladores dde canal de sódio |
| UA116087C2 (uk) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Композиція для лікування вірусу гепатиту c |
| US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
| TW201446286A (zh) * | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
| KR20140119012A (ko) | 2013-01-31 | 2014-10-08 | 길리어드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
| CN104211565A (zh) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
| ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
| CN104513223B (zh) * | 2014-11-20 | 2017-07-14 | 上海众强药业有限公司 | 芴乙酮衍生物的制备方法 |
| US20180008624A1 (en) | 2015-02-13 | 2018-01-11 | Sandoz Ag | Pharmaceutical Compositions Comprising Ledipasvir And Sofosbuvir |
| WO2016145269A1 (en) | 2015-03-12 | 2016-09-15 | Teva Pharmaceuticals International Gmbh | Solid state forms ledipasvir and processes for preparation of ledipasvir |
| CN104788361B (zh) * | 2015-04-21 | 2017-06-30 | 杭州科巢生物科技有限公司 | 5‑氮杂螺[2.4]庚烷‑6‑甲酸衍生物的合成方法 |
| WO2016193919A1 (en) | 2015-06-05 | 2016-12-08 | Mylan Laboratories Limited | Polymorphic form of ledipasvir |
| CN104961733B (zh) * | 2015-07-06 | 2019-04-09 | 上海众强药业有限公司 | 雷迪帕韦晶型及其制备方法 |
| WO2017072596A1 (en) | 2015-10-26 | 2017-05-04 | Optimus Drugs (P) Ltd | An improved process for the preparation of ledipasvir |
| CN106608870A (zh) * | 2015-10-26 | 2017-05-03 | 广东东阳光药业有限公司 | 一种制备雷迪帕韦杂质的方法 |
| CN105237517B (zh) * | 2015-10-30 | 2017-10-27 | 南京正大天晴制药有限公司 | 结晶的雷迪帕韦化合物及其制备方法 |
| WO2017072714A1 (en) | 2015-10-30 | 2017-05-04 | Lupin Limited | Stable ledipasvir premix and process of preparation thereof |
| CN105237384B (zh) * | 2015-11-06 | 2017-06-30 | 上海万溯化学有限公司 | 一种多取代芴衍生物的制备方法 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN106008316B (zh) * | 2016-06-17 | 2018-04-27 | 成都百事兴科技实业有限公司 | 一种合成雷迪帕韦手性中间体的方法 |
| CN106699740A (zh) * | 2016-12-26 | 2017-05-24 | 上海博志研新药物技术有限公司 | 一种雷迪帕韦和索非布韦复方片剂及其制备方法和应用 |
| US10392370B2 (en) | 2017-03-13 | 2019-08-27 | Optimus Drugs Pvt Ltd | Process for the preparation of Daclatasvir dihydrochloride and its intermediates |
| CN109053400A (zh) * | 2018-08-24 | 2018-12-21 | 江苏工程职业技术学院 | 一种雷迪帕韦关键中间体的制备方法 |
| US11378965B2 (en) | 2018-11-15 | 2022-07-05 | Toyota Research Institute, Inc. | Systems and methods for controlling a vehicle based on determined complexity of contextual environment |
| CN109678686A (zh) * | 2018-12-19 | 2019-04-26 | 江苏工程职业技术学院 | 一种抗丙肝药物雷迪帕韦关键中间体的制备方法 |
| JP2024519910A (ja) | 2021-05-21 | 2024-05-21 | ギリアード サイエンシーズ， インコーポレイテッド | ジカウイルス阻害剤としての五環式誘導体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US6482847B2 (en) * | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
| US20070129385A1 (en) * | 2003-08-28 | 2007-06-07 | Sharma Mukesh K | Amorphous valganciclovir hydrochloride |
| CN100448879C (zh) * | 2004-07-22 | 2009-01-07 | 北京化工大学 | 一种无定型头孢呋辛酯的制备方法 |
| US20100076047A1 (en) * | 2007-08-20 | 2010-03-25 | Sankar Reddy Budidet | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt |
| KR20100031045A (ko) * | 2008-09-11 | 2010-03-19 | 씨제이제일제당 (주) | 아데포비어 디피복실의 정제방법 |
| NZ706236A (en) | 2009-05-13 | 2016-07-29 | Gilead Pharmasset Llc | Antiviral compounds |
| WO2010134045A1 (en) * | 2009-05-20 | 2010-11-25 | Ranbaxy Laboratories Limited | Amorphous fosamprenavir calcium |
| CN102471320A (zh) * | 2009-10-16 | 2012-05-23 | 出光兴产株式会社 | 含芴芳香族化合物、有机电致发光元件用材料及使用其的有机电致发光元件 |
| TW201211047A (en) | 2010-06-10 | 2012-03-16 | Gilead Sciences Inc | Methods for treating HCV |
| EP2797586A1 (en) * | 2011-12-29 | 2014-11-05 | AbbVie Inc. | Solid compositions comprising an hcv inhibitor |
| US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
| KR20140119012A (ko) * | 2013-01-31 | 2014-10-08 | 길리어드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
-
2013
- 2013-03-13 US US13/800,374 patent/US8969588B2/en active Active
- 2013-05-31 TW TW102119443A patent/TW201408661A/zh unknown
- 2013-06-03 UY UY0001034844A patent/UY34844A/es not_active Application Discontinuation
- 2013-06-03 AR ARP130101956 patent/AR091259A1/es unknown
- 2013-06-04 WO PCT/US2013/044138 patent/WO2013184698A1/en active Application Filing
- 2013-06-04 MX MX2014014563A patent/MX2014014563A/es unknown
- 2013-06-04 IN IN2644MUN2014 patent/IN2014MN02644A/en unknown
- 2013-06-04 CN CN201380032193.2A patent/CN104379584A/zh active Pending
- 2013-06-04 RU RU2014150437A patent/RU2014150437A/ru not_active Application Discontinuation
- 2013-06-04 CA CA2875507A patent/CA2875507A1/en not_active Abandoned
- 2013-06-04 ES ES13729569.7T patent/ES2694759T3/es active Active
- 2013-06-04 KR KR20147037165A patent/KR20150028971A/ko not_active Application Discontinuation
- 2013-06-04 SG SG11201408013WA patent/SG11201408013WA/en unknown
- 2013-06-04 PT PT13729569T patent/PT2855478T/pt unknown
- 2013-06-04 EP EP13729569.7A patent/EP2855478B1/en active Active
- 2013-06-04 JP JP2015516143A patent/JP2015518891A/ja active Pending
- 2013-06-04 BR BR112014030400A patent/BR112014030400A2/pt not_active Application Discontinuation
- 2013-06-04 CN CN201510929740.8A patent/CN105524050A/zh active Pending
- 2013-06-04 AU AU2013271768A patent/AU2013271768B2/en not_active Ceased
-
2014
- 2014-11-30 IL IL236004A patent/IL236004A0/en unknown
-
2015
- 2015-01-20 US US14/600,911 patent/US9139570B2/en active Active
- 2015-06-23 HK HK15105959.1A patent/HK1205127A1/xx unknown
- 2015-08-13 US US14/825,386 patent/US9682987B2/en active Active
-
2017
- 2017-04-19 JP JP2017083097A patent/JP2017128605A/ja active Pending
- 2017-05-26 US US15/607,326 patent/US20170327488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2855478B1 (en) | 2018-08-08 |
| ES2694759T3 (es) | 2018-12-27 |
| TW201408661A (zh) | 2014-03-01 |
| IL236004A0 (en) | 2015-02-01 |
| US20150141659A1 (en) | 2015-05-21 |
| EP2855478A1 (en) | 2015-04-08 |
| MX2014014563A (es) | 2015-07-06 |
| US8969588B2 (en) | 2015-03-03 |
| WO2013184698A1 (en) | 2013-12-12 |
| US9139570B2 (en) | 2015-09-22 |
| AU2013271768B2 (en) | 2018-05-17 |
| CN105524050A (zh) | 2016-04-27 |
| KR20150028971A (ko) | 2015-03-17 |
| UY34844A (es) | 2013-12-31 |
| IN2014MN02644A (pt) | 2015-10-16 |
| US20150344488A1 (en) | 2015-12-03 |
| JP2017128605A (ja) | 2017-07-27 |
| PT2855478T (pt) | 2018-11-21 |
| US9682987B2 (en) | 2017-06-20 |
| HK1205127A1 (en) | 2015-12-11 |
| CA2875507A1 (en) | 2013-12-12 |
| JP2015518891A (ja) | 2015-07-06 |
| CN104379584A (zh) | 2015-02-25 |
| BR112014030400A2 (pt) | 2016-06-07 |
| RU2014150437A (ru) | 2016-08-10 |
| AR091259A1 (es) | 2015-01-21 |
| US20130324496A1 (en) | 2013-12-05 |
| AU2013271768A1 (en) | 2015-01-15 |
| US20170327488A1 (en) | 2017-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408013WA (en) | Solid forms of an antiviral compound | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201901131VA (en) | Substituted pyrrolizine compounds and uses thereof | |
| SG11201807077RA (en) | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof | |
| SG11201408011SA (en) | Synthesis of antiviral compound | |
| SG11201804294WA (en) | Tank-binding kinase inhibitor compounds | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201408739VA (en) | Inhibitors of hepatitis c virus | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201407115XA (en) | Carboxylic acid compounds | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201810683VA (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
| SG11201407427WA (en) | Extreme pcr | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201408261UA (en) | Syringe | |
| SG11201408263QA (en) | Laver-snack made of laver and cereal sheets and process of producing the same | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201408451WA (en) | Use of vacuum chucks to hold a wafer or wafer sub-stack | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201901460UA (en) | Method for producing the crystalline form of modification a of calcobutrol | |
| SG11201805001UA (en) | Method of treating influenza a |